LFVN trades 19.9% above Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LFVN achieves its forward estimates and maintains a stable P/E multiple of 10.9x. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, LifeVantage Corporation (LFVN) has a Wall Street consensus price target of $5.00, based on estimates from 3 covering analysts. With the stock currently trading at $6.24, this represents a potential downside of -19.9%. The company has a market capitalization of $79M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, LFVN trades at a trailing P/E of 8.2x and forward P/E of 10.9x. Analysts expect EPS to grow +26.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $5.04, with bear and bull scenarios of $3.18 and $6.65 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NATRNature's Sunshine Products, Inc. | $382M | $21.75 | $37.00 | +70.1% | Buy | 18.0x | 4 |
NHTCNatural Health Trends Corp. | $20M | $1.82 | — | — | — | — | — |
QNSTQuinStreet, Inc. | $935M | $16.27 | $15.00 | -7.8% | Buy | 13.4x | 13 |
HLFHerbalife Nutrition Ltd. | $1.4B | $13.14 | $18.50 | +40.8% | Buy | 5.0x | 26 |
USNAUSANA Health Sciences, Inc. | $413M | $22.38 | $35.00 | +56.4% | Hold | 12.9x | 8 |
NUSNu Skin Enterprises, Inc. | $251M | $5.17 | $11.00 | +112.8% | Hold | 5.2x | 11 |
PLBYPlayboy, Inc. | $110M | $1.18 | $12.63 | +970.3% | Buy | — | 8 |
MGICMagic Software Enterprises Ltd. | $853M | $17.38 | $18.50 | +6.4% | Buy | 15.0x | 6 |
HIMSHims & Hers Health, Inc. | $7.9B | $36.17 | $28.69 | -20.7% | Hold | — | 20 |
AMZNAmazon.com, Inc. | $2.6T | $245.98 | $307.77 | +25.1% | Buy | 27.9x | 94 |
Quick answers to the most common questions about buying LFVN stock.
LFVN's consensus price target is $5, -19.9% below the current price of $6.24. The 3 analysts tracking LFVN see downside risk at present valuations.
LFVN has a consensus rating of "Hold" based on 3 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $5 implies -19.9% downside from current levels.
With a forward P/E of 10.8844x, LFVN trades at a relatively low valuation. The consensus target of $5 implies -19.9% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $5 for LFVN, while the most conservative target is $5. The consensus of $5 represents the median expectation. Our quantitative valuation model projects a bull case target of $7 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
LFVN is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LFVN stock forecast based on 3 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $5, with bear/bull scenarios of $3/$7.
Our quantitative valuation model calculates LFVN's fair value at $5 (base case), with a bear case of $3 and bull case of $7. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
LFVN trades at a forward P/E ratio of 10.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 8.2x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on LFVN, with 0 Sell ratings and a price target of $5 (-19.9% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LFVN analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground. Our model's $3-$7 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.